LON:SLN - Silence Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 605
  • Forecasted Upside: 12.87 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 536
▲ +1 (0.19%)

This chart shows the closing price for SLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silence Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLN

Analyst Price Target is GBX 605
▲ +12.87% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is GBX 605, with a high forecast of GBX 605 and a low forecast of GBX 605. The average price target represents a 12.87% upside from the last price of GBX 536.

This chart shows the closing price for SLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Silence Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/19/2021Peel HuntReiterated RatingHoldGBX 605
5/19/2021Peel HuntReiterated RatingHoldGBX 605
2/17/2021Peel HuntReiterated RatingHoldGBX 605
2/17/2021Peel HuntReiterated RatingHoldGBX 605
7/16/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/20/2020Peel HuntReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/14/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/25/2020Peel HuntUpgradeBuyGBX 224 ➝ GBX 605
3/5/2020Peel HuntReiterated RatingHold
2/5/2020Peel HuntReiterated RatingHold
1/27/2020Peel HuntDowngradeHold
1/7/2020Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/19/2019Peel HuntReiterated RatingBuy
11/1/2019Peel HuntReiterated RatingBuy
9/24/2019Peel HuntReiterated RatingBuy
9/12/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/19/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingUnder Review
6/4/2019Peel HuntReiterated RatingUnder Review
5/2/2019Peel HuntReiterated RatingUnder Review
4/25/2019Peel HuntReiterated RatingUnder Review
4/2/2019Peel HuntReiterated RatingUnder Review
3/27/2019Peel HuntReiterated RatingUnder Review
3/11/2019Peel HuntReiterated RatingUnder Review
2/1/2019Peel HuntReiterated RatingUnder Review
1/15/2019Peel HuntReiterated RatingUnder Review
1/7/2019Peel HuntReiterated RatingUnder Review
12/19/2018Peel HuntReiterated RatingUnder Review
12/6/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/10/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/11/2018Peel HuntReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/7/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/18/2018Peel HuntReiterated RatingBuy
7/11/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
5/31/2018Peel HuntReiterated RatingBuy
4/3/2018Peel HuntReiterated RatingBuyGBX 277
3/26/2018Peel HuntReiterated RatingBuyGBX 277
3/6/2018Peel HuntBoost Price TargetBuyGBX 276 ➝ GBX 277
2/1/2018Peel HuntReiterated RatingBuyGBX 275
1/22/2018Peel HuntReiterated RatingBuyGBX 275
1/8/2018Peel HuntReiterated RatingBuyGBX 276
12/28/2017Peel HuntReiterated RatingBuyGBX 275
12/14/2017Peel HuntInitiated CoverageBuyGBX 276
1/9/2017Canaccord GenuityReiterated RatingBuyGBX 249
12/20/2016Canaccord GenuityReiterated RatingBuyGBX 249
9/27/2016Canaccord GenuityBoost Price TargetBuyGBX 233 ➝ GBX 249
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Silence Therapeutics logo
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 536
Low: 531
High: 564

50 Day Range

MA: GBX 581.16
Low: 525
High: 620

52 Week Range

Now: GBX 536
Low: 330
High: 680

Volume

2,530 shs

Average Volume

70,192 shs

Market Capitalization

£480.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Silence Therapeutics?

The following Wall Street analysts have issued research reports on Silence Therapeutics in the last twelve months: Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for SLN.

What is the current price target for Silence Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Silence Therapeutics in the last year. Their average twelve-month price target is GBX 605, suggesting a possible upside of 12.9%. Peel Hunt has the highest price target set, predicting SLN will reach GBX 605 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 605 for Silence Therapeutics in the next year.
View the latest price targets for SLN.

What is the current consensus analyst rating for Silence Therapeutics?

Silence Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SLN, but not buy more shares or sell existing shares.
View the latest ratings for SLN.

How do I contact Silence Therapeutics' investor relations team?

Silence Therapeutics' physical mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company's listed phone number is +44-20-34576900. The official website for Silence Therapeutics is www.silence-therapeutics.com.